National New Drug Development Foundation and Korea Technology Finance Corporation Select Six Companies as "IP-Value Small Giant Companies" Through Drug Value Assessment Linkage

Six Companies, Including Stand Up Therapeutics and Ticaros, Selected
Up to 4 Billion Won in Guarantee Based on Drug Value Assessment... Linked to Investment and Technology Special Listing

The National New Drug Development Foundation announced on August 21 that Stand Up Therapeutics and Ticaros have been selected as "IP-Value Small Giant Companies" through the Drug Value Assessment–IP Guarantee Linkage Support Project, which is being promoted in partnership with the Korea Technology Finance Corporation.

The Korea Technology Finance Corporation selects "IP-Value Small Giant Companies" based on high-level technology value assessments that identify companies with outstanding intellectual property (IP). The Foundation and the Corporation jointly operate a support system that connects drug value assessment with technology finance in order to promote the commercialization of new drug development technologies resulting from the national new drug development program.

Officials from the National New Drug Development Foundation and the Korea Technology Finance Corporation are taking a commemorative photo at the 'IP-Value Small Giant Company Selection Ceremony.' National New Drug Development Foundation

With this round of selections, the total number of companies named "IP-Value Small Giant Companies" through linkage support from the Foundation has increased to six, including Stand Up Therapeutics and Ticaros. The previously selected companies were Kimcell & Gene, Innovo Therapeutics, ProN Therapeutics, and Qurogen.

Companies participating in the linkage support project may receive guarantee support of up to 4 billion won, based on the results of the drug value assessment. Additional follow-up support is available according to each company’s growth stage, such as recommendations for guarantee-linked investments and pre-assessment for technology special listing.

The Foundation plans to expand its linkage support with the Korea Technology Finance Corporation in order to ensure that drug value assessment results are effectively connected to fundraising, attracting investment, and technology special listings, thus facilitating real business commercialization.

Park Young-min, Head of the National New Drug Development Foundation's project division, stated, "The latest selection of IP-Value Small Giant Companies is the result of linking drug value assessment with technology finance and subsequent commercialization. We will further strengthen the connection between evaluation, finance, investment, and other support systems so that outstanding new drug development technologies can lead to tangible growth and commercialization for companies."

This content was produced with the assistance of AI translation services.